The  ||| S:0 E:4 ||| DT
impact  ||| S:4 E:11 ||| NN
of  ||| S:11 E:14 ||| IN
RTOG  ||| S:14 E:19 ||| NNP
0614  ||| S:19 E:24 ||| CD
and  ||| S:24 E:28 ||| CC
RTOG  ||| S:28 E:33 ||| NNP
0933  ||| S:33 E:38 ||| CD
trials  ||| S:38 E:45 ||| NNS
in  ||| S:45 E:48 ||| IN
routine  ||| S:48 E:56 ||| JJ
clinical  ||| S:56 E:65 ||| JJ
practice ||| S:65 E:73 ||| NN
:  ||| S:73 E:75 ||| :
The  ||| S:75 E:79 ||| DT
US  ||| S:79 E:82 ||| NNP
Survey  ||| S:82 E:89 ||| NNP
of  ||| S:89 E:92 ||| IN
Utilization  ||| S:92 E:104 ||| NN
of  ||| S:104 E:107 ||| IN
Memantine  ||| S:107 E:117 ||| NNP
and  ||| S:117 E:121 ||| CC
IMRT  ||| S:121 E:126 ||| NNP
planning  ||| S:126 E:135 ||| NN
for  ||| S:135 E:139 ||| IN
hippocampus  ||| S:139 E:151 ||| JJ
sparing  ||| S:151 E:159 ||| NN
in  ||| S:159 E:162 ||| IN
patients  ||| S:162 E:171 ||| NNS
receiving  ||| S:171 E:181 ||| VBG
whole  ||| S:181 E:187 ||| JJ
brain  ||| S:187 E:193 ||| NN
radiotherapy  ||| S:193 E:206 ||| NN
for  ||| S:206 E:210 ||| IN
brain  ||| S:210 E:216 ||| NN
metastases  ||| S:216 E:227 ||| VBD
Two  ||| S:227 E:231 ||| CD
recent  ||| S:231 E:238 ||| JJ
clinical  ||| S:238 E:247 ||| JJ
trials ||| S:247 E:253 ||| NNS
,  ||| S:253 E:255 ||| ,
phase  ||| S:255 E:261 ||| NN
III  ||| S:261 E:265 ||| NNP
RTOG  ||| S:265 E:270 ||| NNP
0614  ||| S:270 E:275 ||| CD
and  ||| S:275 E:279 ||| CC
phase  ||| S:279 E:285 ||| NN
II  ||| S:285 E:288 ||| NNP
RTOG  ||| S:288 E:293 ||| NNP
0933 ||| S:293 E:297 ||| CD
,  ||| S:297 E:299 ||| ,
showed  ||| S:299 E:306 ||| VBD
some  ||| S:306 E:311 ||| DT
effectiveness  ||| S:311 E:325 ||| NN
of  ||| S:325 E:328 ||| IN
Memantine  ||| S:328 E:338 ||| NNP
and  ||| S:338 E:342 ||| CC
IMRT  ||| S:342 E:347 ||| NNP
planning  ||| S:347 E:356 ||| NN
for  ||| S:356 E:360 ||| IN
hippocampus  ||| S:360 E:372 ||| JJ
sparing ||| S:372 E:379 ||| NN
,  ||| S:379 E:381 ||| ,
among  ||| S:381 E:387 ||| IN
patients  ||| S:387 E:396 ||| NNS
receiving  ||| S:396 E:406 ||| VBG
whole  ||| S:406 E:412 ||| JJ
brain  ||| S:412 E:418 ||| NN
radiotherapy  ||| S:418 E:431 ||| NNS
( ||| S:431 E:432 ||| -LRB-
WBRT ||| S:432 E:436 ||| NNP
)  ||| S:436 E:438 ||| -RRB-
for  ||| S:438 E:442 ||| IN
brain  ||| S:442 E:448 ||| NN
metastases ||| S:448 E:458 ||| NNS
;  ||| S:458 E:460 ||| :
however ||| S:460 E:467 ||| RB
,  ||| S:467 E:469 ||| ,
their  ||| S:469 E:475 ||| PRP$
use  ||| S:475 E:479 ||| NN
in  ||| S:479 E:482 ||| IN
routine  ||| S:482 E:490 ||| JJ
clinical  ||| S:490 E:499 ||| JJ
practice  ||| S:499 E:508 ||| NN
is  ||| S:508 E:511 ||| VBZ
unknown ||| S:511 E:518 ||| JJ
.  ||| S:518 E:520 ||| .
A  ||| S:520 E:522 ||| DT
survey  ||| S:522 E:529 ||| NN
was  ||| S:529 E:533 ||| VBD
sent  ||| S:533 E:538 ||| VBN
to  ||| S:538 E:541 ||| TO
1933  ||| S:541 E:546 ||| CD
radiation  ||| S:546 E:556 ||| NN
oncologists  ||| S:556 E:568 ||| NN
in  ||| S:568 E:571 ||| IN
the  ||| S:571 E:575 ||| DT
US ||| S:575 E:577 ||| NNP
.  ||| S:577 E:579 ||| .
Data  ||| S:579 E:584 ||| NNP
collected  ||| S:584 E:594 ||| VBD
included  ||| S:594 E:603 ||| VBN
utilization  ||| S:603 E:615 ||| NN
of  ||| S:615 E:618 ||| IN
Memantine  ||| S:618 E:628 ||| NNP
and  ||| S:628 E:632 ||| CC
hippocampus  ||| S:632 E:644 ||| JJ
sparing ||| S:644 E:651 ||| NN
,  ||| S:651 E:653 ||| ,
reasons  ||| S:653 E:661 ||| NNS
for  ||| S:661 E:665 ||| IN
adoption  ||| S:665 E:674 ||| NN
and  ||| S:674 E:678 ||| CC
non-adoption ||| S:678 E:690 ||| JJ
,  ||| S:690 E:692 ||| ,
and  ||| S:692 E:696 ||| CC
demographic  ||| S:696 E:708 ||| JJ
variables ||| S:708 E:717 ||| NNS
.  ||| S:717 E:719 ||| .
A  ||| S:719 E:721 ||| DT
total  ||| S:721 E:727 ||| NN
of  ||| S:727 E:730 ||| IN
196  ||| S:730 E:734 ||| CD
radiation  ||| S:734 E:744 ||| NN
oncologists  ||| S:744 E:756 ||| NNS
responded  ||| S:756 E:766 ||| VBD
to  ||| S:766 E:769 ||| TO
the  ||| S:769 E:773 ||| DT
survey ||| S:773 E:779 ||| NN
,  ||| S:779 E:781 ||| ,
with  ||| S:781 E:786 ||| IN
64 ||| S:786 E:788 ||| CD
%  ||| S:788 E:790 ||| NN
reporting  ||| S:790 E:800 ||| NN
using  ||| S:800 E:806 ||| VBG
Memantine  ||| S:806 E:816 ||| NNP
in  ||| S:816 E:819 ||| IN
almost  ||| S:819 E:826 ||| RB
none  ||| S:826 E:831 ||| NN
of  ||| S:831 E:834 ||| IN
the  ||| S:834 E:838 ||| DT
patients  ||| S:838 E:847 ||| NNS
receiving  ||| S:847 E:857 ||| VBG
WBRT  ||| S:857 E:862 ||| NNP
for  ||| S:862 E:866 ||| IN
brain  ||| S:866 E:872 ||| NN
metastases ||| S:872 E:882 ||| NN
,  ||| S:882 E:884 ||| ,
and  ||| S:884 E:888 ||| CC
only  ||| S:888 E:893 ||| RB
11 ||| S:893 E:895 ||| CD
%  ||| S:895 E:897 ||| NN
considering  ||| S:897 E:909 ||| VBG
Memantine  ||| S:909 E:919 ||| NNP
for  ||| S:919 E:923 ||| IN
< ||| S:923 E:924 ||| SYM
10 ||| S:924 E:926 ||| CD
%  ||| S:926 E:928 ||| NN
of  ||| S:928 E:931 ||| IN
their  ||| S:931 E:937 ||| PRP$
patients ||| S:937 E:945 ||| NNS
.  ||| S:945 E:947 ||| .
The  ||| S:947 E:951 ||| DT
most  ||| S:951 E:956 ||| RBS
common  ||| S:956 E:963 ||| JJ
reason  ||| S:963 E:970 ||| NN
for  ||| S:970 E:974 ||| IN
not  ||| S:974 E:978 ||| RB
using  ||| S:978 E:984 ||| VBG
Memantine  ||| S:984 E:994 ||| NNP
was  ||| S:994 E:998 ||| VBD
a  ||| S:998 E:1000 ||| DT
poor  ||| S:1000 E:1005 ||| JJ
patient  ||| S:1005 E:1013 ||| NN
performance  ||| S:1013 E:1025 ||| NN
status ||| S:1025 E:1031 ||| NN
,  ||| S:1031 E:1033 ||| ,
and  ||| S:1033 E:1037 ||| CC
limited  ||| S:1037 E:1045 ||| JJ
life  ||| S:1045 E:1050 ||| NN
expectancy ||| S:1050 E:1060 ||| NN
.  ||| S:1060 E:1062 ||| .
Likewise ||| S:1062 E:1070 ||| RB
,  ||| S:1070 E:1072 ||| ,
56 ||| S:1072 E:1074 ||| CD
%  ||| S:1074 E:1076 ||| NN
of  ||| S:1076 E:1079 ||| IN
radiation  ||| S:1079 E:1089 ||| NN
oncologists  ||| S:1089 E:1101 ||| NNS
would  ||| S:1101 E:1107 ||| MD
not  ||| S:1107 E:1111 ||| RB
change  ||| S:1111 E:1118 ||| VB
their  ||| S:1118 E:1124 ||| PRP$
clinical  ||| S:1124 E:1133 ||| JJ
practice  ||| S:1133 E:1142 ||| NN
to  ||| S:1142 E:1145 ||| TO
include  ||| S:1145 E:1153 ||| VB
hippocampus  ||| S:1153 E:1165 ||| JJ
sparing  ||| S:1165 E:1173 ||| JJ
IMRT  ||| S:1173 E:1178 ||| NN
in  ||| S:1178 E:1181 ||| IN
patients  ||| S:1181 E:1190 ||| NNS
receiving  ||| S:1190 E:1200 ||| VBG
WBRT  ||| S:1200 E:1205 ||| NNS
based  ||| S:1205 E:1211 ||| VBN
on  ||| S:1211 E:1214 ||| IN
the  ||| S:1214 E:1218 ||| DT
results  ||| S:1218 E:1226 ||| NNS
of  ||| S:1226 E:1229 ||| IN
RTOG  ||| S:1229 E:1234 ||| NNP
0933 ||| S:1234 E:1238 ||| CD
.  ||| S:1238 E:1240 ||| .
Further  ||| S:1240 E:1248 ||| JJ
validation  ||| S:1248 E:1259 ||| NN
of  ||| S:1259 E:1262 ||| IN
hippocampus  ||| S:1262 E:1274 ||| JJ
sparing  ||| S:1274 E:1282 ||| NN
in  ||| S:1282 E:1285 ||| IN
a  ||| S:1285 E:1287 ||| DT
phase  ||| S:1287 E:1293 ||| NN
III  ||| S:1293 E:1297 ||| NNP
trial  ||| S:1297 E:1303 ||| NN
was  ||| S:1303 E:1307 ||| VBD
supported  ||| S:1307 E:1317 ||| VBN
by  ||| S:1317 E:1320 ||| IN
71 ||| S:1320 E:1322 ||| CD
%  ||| S:1322 E:1324 ||| NN
of  ||| S:1324 E:1327 ||| IN
radiation  ||| S:1327 E:1337 ||| NN
oncologists ||| S:1337 E:1348 ||| NN
,  ||| S:1348 E:1350 ||| ,
whereas  ||| S:1350 E:1358 ||| IN
further  ||| S:1358 E:1366 ||| JJ
exploration  ||| S:1366 E:1378 ||| NN
of  ||| S:1378 E:1381 ||| IN
Memantine  ||| S:1381 E:1391 ||| NNP
for  ||| S:1391 E:1395 ||| IN
this  ||| S:1395 E:1400 ||| DT
purpose  ||| S:1400 E:1408 ||| NN
in  ||| S:1408 E:1411 ||| IN
a  ||| S:1411 E:1413 ||| DT
phase  ||| S:1413 E:1419 ||| NN
III  ||| S:1419 E:1423 ||| NNP
trial  ||| S:1423 E:1429 ||| NN
was  ||| S:1429 E:1433 ||| VBD
supported  ||| S:1433 E:1443 ||| VBN
by  ||| S:1443 E:1446 ||| IN
42 ||| S:1446 E:1448 ||| CD
% ||| S:1448 E:1449 ||| NN
.  ||| S:1449 E:1451 ||| .
At  ||| S:1451 E:1454 ||| IN
this  ||| S:1454 E:1459 ||| DT
time ||| S:1459 E:1463 ||| NN
,  ||| S:1463 E:1465 ||| ,
the  ||| S:1465 E:1469 ||| DT
majority  ||| S:1469 E:1478 ||| NN
of  ||| S:1478 E:1481 ||| IN
surveyed  ||| S:1481 E:1490 ||| JJ
radiation  ||| S:1490 E:1500 ||| NN
oncologists  ||| S:1500 E:1512 ||| NN
in  ||| S:1512 E:1515 ||| IN
the  ||| S:1515 E:1519 ||| DT
US  ||| S:1519 E:1522 ||| NNP
do  ||| S:1522 E:1525 ||| VBP
not  ||| S:1525 E:1529 ||| RB
use  ||| S:1529 E:1533 ||| VB
Memantine ||| S:1533 E:1542 ||| NNP
,  ||| S:1542 E:1544 ||| ,
or  ||| S:1544 E:1547 ||| CC
IMRT  ||| S:1547 E:1552 ||| NNP
planning  ||| S:1552 E:1561 ||| NN
for  ||| S:1561 E:1565 ||| IN
hippocampus  ||| S:1565 E:1577 ||| JJ
sparing  ||| S:1577 E:1585 ||| NN
in  ||| S:1585 E:1588 ||| IN
patients  ||| S:1588 E:1597 ||| NNS
receiving  ||| S:1597 E:1607 ||| VBG
WBRT ||| S:1607 E:1611 ||| NNP
.  ||| S:1611 E:1613 ||| .
Further  ||| S:1613 E:1621 ||| JJ
validation  ||| S:1621 E:1632 ||| NN
of  ||| S:1632 E:1635 ||| IN
the  ||| S:1635 E:1639 ||| DT
hippocampus  ||| S:1639 E:1651 ||| JJ
sparing  ||| S:1651 E:1659 ||| JJ
concept  ||| S:1659 E:1667 ||| NN
in  ||| S:1667 E:1670 ||| IN
a  ||| S:1670 E:1672 ||| DT
phase  ||| S:1672 E:1678 ||| NN
III  ||| S:1678 E:1682 ||| NNP
trial  ||| S:1682 E:1688 ||| NN
was  ||| S:1688 E:1692 ||| VBD
supported ||| S:1692 E:1701 ||| VBN
,  ||| S:1701 E:1703 ||| ,
before  ||| S:1703 E:1710 ||| IN
adopting  ||| S:1710 E:1719 ||| VBG
it  ||| S:1719 E:1722 ||| PRP
in  ||| S:1722 E:1725 ||| IN
routine  ||| S:1725 E:1733 ||| JJ
clinical  ||| S:1733 E:1742 ||| JJ
practice ||| S:1742 E:1750 ||| NN
.  ||| S:1750 E:1752 ||| .
